<DOC>
	<DOCNO>NCT01027364</DOCNO>
	<brief_summary>The primary objective study : evaluate safety tolerability rFIXFc ; evaluate efficacy rFIXFc treatment arm ; evaluate effectiveness prophylaxis on-demand ( episodic ) therapy compare annualized number bleed episodes participant receive rFIXFc prevention ( prophylaxis ) regimen participant receive rFIXFc episodic regimen . The secondary objective study : evaluate ass pharmacokinetic ( PK ) parameter estimate rFIXFc rFIX ( BeneFIX® ) baseline Sequential PK subgroup well rFIXFc Week 26 ( ±1 week ) ; evaluate participant ' response treatment ; evaluate rFIXFc consumption .</brief_summary>
	<brief_title>Study Recombinant Factor IX Fc Fusion Protein ( rFIXFc ) Participants With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Male 12 year age old weigh least 40 kg Diagnosed hemophilia B ( baseline Factor IX level less equal 2 % ) History least 100 exposure day Factor IX product Platelet count ≥100,000 cells/μL History Factor IX inhibitor Kidney liver dysfunction Diagnosed another coagulation defect hemophilia B Prior history anaphylaxis associate Factor IX intravenous ( IV ) immunoglobulin administration</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>